Reporting from the frontiers of health & medicine.
Explore all of our newsletters here: https://www.statnews.com/signup/
STAT
Loading...
Trump administration guidance reignites debate over methadone and buprenorphine www.statnews.com/2026/06/10/m...
The condemnations keep coming after five diabetes experts were escorted out of an ADA meeting for handing out copies of an editorial criticizing federal research cuts. www.statnews.com/2026/06/09/a...
The American College of Obstetricians and Gynecologists has released a recommended vaccine schedule during pregnancy, one that diverges from CDC guidance. www.statnews.com/2026/06/10/a...
STAT is sticking with ‘health care’ www.statnews.com/2026/06/09/h...
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments. www.statnews.com/2026/06/08/a...
Federal health regulators on Tuesday signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years. www.statnews.com/2026/06/09/n...
A government-commissioned study had been meant to inform new dietary guidelines, and found risks associated with even light drinking. www.statnews.com/2026/06/09/s...
STAT
STAT
#Breaking: NIAID appoints new acting director after weeks-long questions over leadership www.statnews.com/2026/06/09/n...
Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients. www.statnews.com/2026/06/08/p...
STAT
STAT
STAT
STAT
STAT
STAT
STAT
The condemnations keep coming after five diabetes experts were escorted out of an ADA meeting for handing out copies of an editorial criticizing federal research cuts.
The American College of Obstetricians and Gynecologists has released a recommended vaccine schedule during pregnancy, one that diverges from CDC guidance.
www.statnews.com
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
The NIH has appointed researcher John Powers III to lead its infectious disease institute on an acting basis, after weeks of being in leadership limbo.
www.statnews.com
A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.
In a report published on the first anniversary of the Bethesda Declaration, 71 staffers write that they feel NIH leadership “largely ignored" their concerns www.statnews.com/2026/06/09/n...
STAT
In a report published on the first anniversary of the Bethesda Declaration, 71 staffers write that they feel NIH leadership “largely ignored" their concerns.
